A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

I4C-MC-JTBF -

The purpose of this study is to find a recommended schedule and dose range for LY2875358 when given with ramucirumab that may be safely given to participants with cancer. In Part A of this study, escalating doses of LY2875358 will be given in combination with a fixed dose of ramucirumab to evaluate the safety of the combination. After a recommended schedule and dose range of LY2875358 and ramucirumab has been established, Part B of the study will confirm safety and to see how well certain tumors respond to the combination of study drugs.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Advanced Cancer
What the trial is testing?
Ramucirumab, LY2875358
Could I receive a Placebo?
No
Enrollment Goal
97
Trial Dates
Mar 7, 2014 - Jan 24, 2018
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment and how many cycles of treatment you receive.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.